Uncommon mutations present unique challenges in cancer treatments, especially when it comes to EGFR mutations. In the 2022 Targeted Therapies Forum, Dr. Angel Qin and Millie Das provide a comprehensive breakdown of the treatment protocols for these mutations and delve into the intricate issues surrounding insurance complications for mutation testing.
Our gratitude extends to our supportive sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, for their dedication to the betterment of cancer research and patient care.
Stay informed and ahead in the evolving landscape of cancer treatments. Explore more insights at http://cancerGRACE.org/. For an interactive experience, join our community and start a discussion at https://cancergrace.org/forum.